The company's lead product candidate, APG101, is currently in a controlled phase II proof of concept study with GBM patients. Apogenix's platform targets critical pathways involved in the proliferation, migration, and apoptosis of diseased cells, boosting the immune response cycle to strengthen and prolong the anti-tumor immune response. The company also develops innovative immunotherapeutics for the treatment of viral infections, such as COVID-19, by reducing lymphopenia and inflammatory cell death in patients and restoring the anti-tumor immune response in cancer patients through different TNFSF-dependent signaling pathways.